# Castle Biosciences share price today (Castle Biosciences, Inc., CSTL)

> Castle Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CSTL · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/cstl

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $35.14 (+37.8% in a year)
- Revenue (Jun 2026): $104 M (+20.1% on a year ago)
- Profit (Jun 2026): −$2.1 M (−145.5% on a year ago)
- Operating margin: −3.0% (+1.9 points on a year ago)
- ROE: −5%, FY25
- ROIC: −5.0%, against a 9.2% cost of capital: −14.2 points

The main question: the share price moved +37.8% in a year while yearly earnings per share moved −234.4%. The difference came from the market paying a higher multiple. ## What is the Castle Biosciences share price today? Castle Biosciences, Inc.'s share price was $35.14 at the close on 3 November 2026. That is 23.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $19 and $42, and at that close it sat 69% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 1 year the share price moved +79% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Castle Biosciences pay? Castle Biosciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Castle Biosciences on? Castle Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Castle Biosciences profitable? Castle Biosciences, Inc. posted a net loss of $2.1 M in the Jun 2026 quarter. The full FY25 year was a loss of $24.2 M. That loss is 2.0% of the quarter's revenue. The same quarter a year earlier earned $4.5 M. 8 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$2.1 M, −145.5% on a year earlier. For the full year, FY25 profit was −$24.2 M (−232.4% on the year before). Why profit moved: revenue changed +20.1% on a year earlier and the margin moved +1.9 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −130.6% and revenue +3.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Castle Biosciences make, and is it growing? Castle Biosciences, Inc. reported $104 M of revenue in the Jun 2026 quarter, +20.1% on the same quarter a year earlier. Over 4 years it has grown 38.3% a year on average. The last full year, FY25, came in at $344 M. The last four reported quarters add to $357 M. FY25 revenue was $344 M, +3.7% on the year before. Recent pace: the last four quarters grew +3.2% on average, against 38.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.2%, against +11.5% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Castle Biosciences keep? Castle Biosciences, Inc.'s operating margin was −3.0% in the Jun 2026 quarter, 1.9 percentage points higher than the same quarter a year ago. Across 5 years it has been between −66.5% and 2.6%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.9 percentage points on the year while gross margin changed −2.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Castle Biosciences' profit turning into cash? Castle Biosciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $64.3 M of operating cash against −$24.2 M of profit. After $36.0 M of spending on assets, $28.3 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Castle Biosciences' cash go? Castle Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $78.0 M on assets over the last 3 years. Averaged over those years that is 7.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $78.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Castle Biosciences' P/E ratio, and how does it compare with its own history? Castle Biosciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Castle Biosciences, Inc. at 3.1× its FY25 revenue of $344 M. The P/E comes back here once profit turns positive. Why the multiple is where it is: over the past year earnings per share moved −234.4% while the price moved +37.8%. The price did better than earnings, which pushed the multiple up within its own range. ## Is the Castle Biosciences business getting better or worse? Castle Biosciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Castle Biosciences earn on its capital? Castle Biosciences, Inc. earned a ROE of −5% in FY25. That is up from a low of −17% in FY22. Its return on capital used (ROIC) is 14.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −7.0% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −7.0% net margin × 0.59× asset turnover × 1.23× leverage (assets divided by equity) ≈ −5.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −5.0% − 9.2% = −14.2 percentage points. The 9.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −5.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −11.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Castle Biosciences have too much debt? Castle Biosciences, Inc. has total debt of $36.6 M against shareholder equity of $470 M as of Jun 2026, so its debt is 0.08× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.08 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Castle Biosciences shareholding pattern? 7.4% of Castle Biosciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Castle Biosciences from balance-sheet trouble? For Castle Biosciences, Inc., the Z-score is 5.77. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.77 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Castle Biosciences rank in its industry? 35.7 out of 100, rank 28 of 30 in Diagnostics & Research, with 64% of the evidence available. Castle Biosciences, Inc. scores 35.7 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 28. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.7 + 6.6 + 11.2 + 5.2 = 35.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Castle Biosciences compared with? Castle Biosciences ranks 28 of 30 Diagnostics & Research companies on the 4-Factor Sector Score, with 35.7 out of 100. 1. [CareDx, Inc.](https://www.sectoralpha.in/us/stocks/cdna) CDNA · leader · Evidence leans up · 64% evidence 62.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 33.9% · Profit 93.1% · Operating margin change 12.6 points · 62% evidence Capital efficiency 7.2/25 · ROCE -0.4% · Operating margin 0.2% · 76% evidence Valuation 10.6/20 · P/E 13.3× · PEG n/a · 15% evidence Relative strength 19.9/20 · Lead over its industry 110.8% · Lead over S&P 500 166.5% · 1 year 466.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.1 + 7.2 + 10.6 + 19.9 = 62.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Agilent Technologies, Inc.](https://www.sectoralpha.in/us/stocks/a) A · leader · Evidence leans up · 85% evidence 62.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 8.6% · Profit 18% · Operating margin change 2.9 points · 95% evidence Capital efficiency 18.4/25 · ROCE 15.4% · Operating margin 25.6% · 76% evidence Valuation 11.1/20 · P/E 27.1× · PEG 1.41 · 65% evidence Relative strength 11.7/20 · Lead over its industry -8.9% · Lead over S&P 500 21.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.8 + 18.4 + 11.1 + 11.7 = 62 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Medpace Holdings, Inc.](https://www.sectoralpha.in/us/stocks/medp) MEDP · leader · Evidence leans up · 85% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 20.3% · Profit 19.4% · Operating margin change 1.6 points · 95% evidence Capital efficiency 21.3/25 · ROCE 75.3% · Operating margin 23.1% · 76% evidence Valuation 12.2/20 · P/E 33.6× · PEG 1.29 · 65% evidence Relative strength 8.7/20 · Lead over its industry -11.9% · Lead over S&P 500 17.3% · 1 year 12.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.1 + 21.3 + 12.2 + 8.7 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Revvity, Inc.](https://www.sectoralpha.in/us/stocks/rvty) RVTY · leader · Too little evidence to rank firmly · 58% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue n/a · Profit n/a · Operating margin change 3.3 points · 45% evidence Capital efficiency 12.8/25 · ROCE 4.3% · Operating margin 17.1% · 76% evidence Valuation 8.8/20 · P/E 53.4× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 7% · Lead over S&P 500 41.6% · 1 year 80.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 12.8 + 8.8 + 18.2 = 60.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [IDEXX Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/idxx) IDXX · turning · Evidence leans up · 81% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/35 · Revenue 12.8% · Profit 15.5% · Operating margin change 1.4 points · 83% evidence Capital efficiency 21.3/25 · ROCE 68.1% · Operating margin 35% · 76% evidence Valuation 7.1/20 · P/E 36.4× · PEG 1.97 · 65% evidence Relative strength 8.0/20 · Lead over its industry -21.5% · Lead over S&P 500 6.4% · 1 year -5.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.1 + 21.3 + 7.1 + 8 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Labcorp Holdings Inc.](https://www.sectoralpha.in/us/stocks/lh) LH · leader · Evidence leans up · 81% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.3/35 · Revenue 6.4% · Profit 31.2% · Operating margin change 0.9 points · 83% evidence Capital efficiency 13.4/25 · ROCE 9.9% · Operating margin 12.2% · 76% evidence Valuation 15.2/20 · P/E 22.9× · PEG 0.69 · 65% evidence Relative strength 8.9/20 · Lead over its industry -11.1% · Lead over S&P 500 19.1% · 1 year 40% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.3 + 13.4 + 15.2 + 8.9 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [GRAIL, Inc.](https://www.sectoralpha.in/us/stocks/gral) GRAL · leader · Evidence leans up · 61% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 23% · Profit n/a · Operating margin change 36.1 points · 62% evidence Capital efficiency 3.9/25 · ROCE -19.3% · Operating margin -332% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.4/20 · Lead over its industry 25.5% · Lead over S&P 500 63.9% · 1 year 75.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.9 + 3.9 + 10 + 19.4 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Mettler-Toledo International Inc.](https://www.sectoralpha.in/us/stocks/mtd) MTD · leader · Evidence leans up · 81% evidence 55.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.0/35 · Revenue 6.9% · Profit 9% · Operating margin change 3.8 points · 83% evidence Capital efficiency 21.0/25 · ROCE 47.8% · Operating margin 31.2% · 76% evidence Valuation 6.8/20 · P/E 28.5× · PEG 2.27 · 65% evidence Relative strength 11.1/20 · Lead over its industry -11% · Lead over S&P 500 19.2% · 1 year 18% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17 + 21 + 6.8 + 11.1 = 55.9 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 9. [Natera, Inc.](https://www.sectoralpha.in/us/stocks/ntra) NTRA · leader · Evidence leans up · 64% evidence 54.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 37.8% · Profit n/a · Operating margin change 9.9 points · 62% evidence Capital efficiency 5.3/25 · ROCE -13.5% · Operating margin -10.3% · 76% evidence Valuation 11.4/20 · P/E -152.2× · PEG n/a · 15% evidence Relative strength 13.7/20 · Lead over its industry 9% · Lead over S&P 500 42.8% · 1 year 94.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 5.3 + 11.4 + 13.7 = 54.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Charles River Laboratories International, Inc.](https://www.sectoralpha.in/us/stocks/crl) CRL · leader · Evidence leans up · 64% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.6/35 · Revenue -0.7% · Profit n/a · Operating margin change -1.6 points · 62% evidence Capital efficiency 12.0/25 · ROCE 7.9% · Operating margin 15.1% · 76% evidence Valuation 11.3/20 · P/E -87.6× · PEG n/a · 15% evidence Relative strength 18.1/20 · Lead over its industry 17.8% · Lead over S&P 500 54.6% · 1 year 109.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.6 + 12 + 11.3 + 18.1 = 53 · What this means: Relative strength against the index is 54.6%, and revenue and profit growth are weak. 11. [Quest Diagnostics Incorporated](https://www.sectoralpha.in/us/stocks/dgx) DGX · leader · Evidence leans up · 85% evidence 52.7 out of 100 Growth Capital Valuation Relative
12. [Adaptive Biotechnologies Corporation](https://www.sectoralpha.in/us/stocks/adpt) ADPT · leader · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative
13. [Sotera Health Company](https://www.sectoralpha.in/us/stocks/shc) SHC · quiet · Evidence leans up · 71% evidence 51.3 out of 100 Growth Capital Valuation Relative
14. [IQVIA Holdings Inc.](https://www.sectoralpha.in/us/stocks/iqv) IQV · leader · Evidence leans up · 81% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [BillionToOne, Inc.](https://www.sectoralpha.in/us/stocks/blln) BLLN · turning · Too little evidence to rank firmly · 58% evidence 49.0 out of 100 Growth Capital Valuation Relative
16. [Danaher Corporation](https://www.sectoralpha.in/us/stocks/dhr) DHR · breaking out · Evidence leans down · 85% evidence 48.6 out of 100 Growth Capital Valuation Relative
17. [Illumina, Inc.](https://www.sectoralpha.in/us/stocks/ilmn) ILMN · leader · Evidence leans down · 71% evidence 48.4 out of 100 Growth Capital Valuation Relative
18. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) OPK · turning · Evidence leans down · 64% evidence 48.2 out of 100 Growth Capital Valuation Relative
19. [Guardant Health, Inc.](https://www.sectoralpha.in/us/stocks/gh) GH · turning · Evidence leans down · 61% evidence 48.2 out of 100 Growth Capital Valuation Relative
20. [Veracyte, Inc.](https://www.sectoralpha.in/us/stocks/vcyt) VCYT · turning · Evidence leans down · 64% evidence 47.5 out of 100 Growth Capital Valuation Relative
21. [NeoGenomics, Inc.](https://www.sectoralpha.in/us/stocks/neo) NEO · losing its lead · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
22. [Twist Bioscience Corporation](https://www.sectoralpha.in/us/stocks/twst) TWST · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
23. [Qiagen N.V.](https://www.sectoralpha.in/us/stocks/qgen) QGEN · breaking out · Evidence leans down · 81% evidence 45.0 out of 100 Growth Capital Valuation Relative
24. [Thermo Fisher Scientific Inc.](https://www.sectoralpha.in/us/stocks/tmo) TMO · leader · Evidence leans down · 85% evidence 44.8 out of 100 Growth Capital Valuation Relative
25. [RadNet, Inc.](https://www.sectoralpha.in/us/stocks/rdnt) RDNT · breaking out · Evidence leans down · 64% evidence 41.9 out of 100 Growth Capital Valuation Relative
26. [Waters Corporation](https://www.sectoralpha.in/us/stocks/wat) WAT · leader · Too little evidence to rank firmly · 58% evidence 39.2 out of 100 Growth Capital Valuation Relative
27. [ICON Public Limited Company](https://www.sectoralpha.in/us/stocks/iclr) ICLR · turning · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative
28. Castle Biosciences, Inc. this page CSTL · breaking out · Evidence leans down · 64% evidence 35.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.7/35 · Revenue 3.5% · Profit n/a · Operating margin change 1.9 points · 62% evidence Capital efficiency 6.6/25 · ROCE -6.4% · Operating margin -3% · 76% evidence Valuation 11.2/20 · P/E -62.3× · PEG n/a · 15% evidence Relative strength 5.2/20 · Lead over its industry -17.3% · Lead over S&P 500 9.9% · 1 year 6.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.7 + 6.6 + 11.2 + 5.2 = 35.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 29. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) PSNL · turning · Most evidence points down · 61% evidence 33.1 out of 100 Growth Capital Valuation Relative
30. [GeneDx Holdings Corp.](https://www.sectoralpha.in/us/stocks/wgs) WGS · quiet · Most evidence points down · 71% evidence 24.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics & Research](https://www.sectoralpha.in/us/sectors/diagnostics-research), all 30 compared on one page. ## Which companies are close to Castle Biosciences in size? Castle Biosciences is the 30th largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: GeneDx Holdings Corp., Personalis, Inc. and OPKO Health, Inc. Just below it: Myriad Genetics, Inc., Fulgent Genetics, Inc. and Biodesix, Inc. ### Diagnostics & Research companies close in size

1. [GeneDx Holdings Corp.](https://www.sectoralpha.in/us/stocks/wgs) $2 billion
2. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) $1.7 billion
3. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) $1.3 billion
4. Castle Biosciences, Inc. $1.1 billion
5. [Myriad Genetics, Inc.](https://www.sectoralpha.in/us/stocks/mygn) $578 million
6. [Fulgent Genetics, Inc.](https://www.sectoralpha.in/us/stocks/flgt) $533 million
7. [Biodesix, Inc.](https://www.sectoralpha.in/us/stocks/bdsx) $222 million

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Power Solutions International, Inc.](https://www.sectoralpha.in/us/stocks/psix) $1.1 billion · Specialty Industrial Machinery
2. [Janux Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/janx) $1.1 billion · Biotechnology
3. Castle Biosciences, Inc. $1.1 billion
4. [Inhibrx Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/inbx) $1.1 billion · Biotechnology
5. [Loma Negra Compañía Industrial Argentina Sociedad Anónima](https://www.sectoralpha.in/us/stocks/loma) $1.1 billion · Building Materials

## What else do people ask about Castle Biosciences? ### What were Castle Biosciences's latest quarterly results? Castle Biosciences, Inc. reported revenue of $104 M and a net loss of $2.1 M for the Jun 2026 quarter. Revenue rose 20.1% and profit fell 145.5% compared with a year earlier. Earnings per share were −$0.07. The operating margin was −3.0%, 1.9 percentage points higher than a year earlier (as of 3 November 2026). ### What is Castle Biosciences's market cap? Castle Biosciences, Inc.'s market capitalisation is $1.1 B at a stock price of $35.14. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Castle Biosciences performing? Castle Biosciences, Inc.'s latest readings are below. In its latest quarter, revenue rose 20.1% and profit fell 145.5% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Castle Biosciences's stock price go up? This page does not forecast Castle Biosciences, Inc.'s stock price. What it shows instead: the stock price is $35.14. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Castle Biosciences in its business cycle? Castle Biosciences, Inc.'s FY25 operating margin was −6.6%, against a 5-year range of −66.5% to 2.6%: the middle of its own range, neither a peak nor a low. The latest quarter was −3.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Castle Biosciences story? The main question: the share price moved +37.8% in a year while yearly earnings per share moved −234.4%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Castle Biosciences a stock worth studying right now? What the numbers show: Castle Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.